Comparative Pharmacology
Head-to-head clinical analysis: ISORDIL versus NITRONAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISORDIL versus NITRONAL.
ISORDIL vs NITRONAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide dinitrate is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylate cyclase, increasing cGMP, leading to vasodilation of veins (greater effect) and arteries. Reduces preload and afterload, decreasing myocardial oxygen demand.
Nitronal (nitroglycerin) is a vasodilator that works by releasing nitric oxide, which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) in vascular smooth muscle, leading to relaxation and dilation of peripheral arteries and veins, predominantly venous dilation.
Isosorbide dinitrate: initial 5-20 mg orally 2-3 times daily, maintenance 10-40 mg orally 2-3 times daily. Sublingual: 2.5-5 mg every 15 minutes for up to 3 doses for acute angina. Extended-release: 40 mg orally once daily, increased to 80 mg once daily as tolerated.
Initial intravenous infusion of 5 mcg/min, titrated by 5 mcg/min every 3-5 minutes to clinical effect; typical maintenance 10-200 mcg/min.
None Documented
None Documented
Terminal half-life: 1–4 hours (isosorbide dinitrate); clinical context: short duration requires frequent dosing or sustained-release formulations.
Terminal elimination half-life is 1-4 minutes (due to rapid hepatic metabolism via glutathione S-transferase). Clinical context: necessitates continuous IV infusion for sustained effect.
Renal: 80% as inactive metabolites; biliary/fecal: 20% as conjugates.
Renal: ~60% as inactive metabolites; fecal: ~35% via bile; unchanged drug: <1%.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator